Compare Gitlab Inc (GTLB) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Tilray Brands Inc — how do they compare? Gitlab Inc trades at $31.91 (market cap $5.54B), while Tilray Brands Inc trades at $4.38 (market cap $541.36M). The key difference: Gitlab Inc is far larger — about 10.2× Tilray Brands Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | TLRY | |
|---|---|---|
Market Cap | $5.54B | $541.36M |
Sector | Technology | Health |
52-Week High | $51.04 | $21.00 |
52-Week Low | $19.42 | $4.31 |
Enterprise Value | $4.29B | $638.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $32.98, down 1.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.50. The company reported strong revenue growth to $759 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven software development, including a fourth consecutive Leader recognition in Gartner's Magic Quadrant as of June 2026.
Outlook: GitLab's strategic position in the AI and DevSecOps space offers growth potential, but high valuation multiples and persistent losses pose risks. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Key catalysts include execution on profitability and enterprise adoption of AI tools, while competitive pressures and macroeconomic headwinds remain concerns.
TLRY trades at $4.355, down 0.57% on the day, amid a bearish technical signal and weak earnings performance. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, while revenue grew to $821.31 million. Recent news includes medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.
The outlook remains challenging due to persistent losses and high debt levels, though low valuation ratios like P/S of 0.55 and P/B of 0.35 may attract value investors. Key risks include profitability struggles, regulatory uncertainty, and competitive pressures in the cannabis sector. Analyst sentiment is mixed, with 65% hold ratings reflecting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
